An early classification of primary prevention distinguishes among primary, secondary, and tertiary forms (Caplan, 1964). Tertiary prevention, or rehabilitation, focuses on reducing severity and discomfort. Secondary prevention focuses on early detection and treatment while primary prevention focuses on reducing incidence. Bloom (1979) stresses the limitations of this conceptual framework of primary prevention, mainly the inability to identify a “precondition” or “cause” in various forms of illness especially mental illness. He describes a paradigm shift which assumes that “we are all variously vulnerable to stressful life events” and that “reducing the incidence of particular stressful life events” becomes the focus of prevention initiatives, thereby eliminating the need to identify a unique cause for each disorder. This paradigm shifts focus from targeting populations with predisposing biopsychosocial risk factors to identifying precipitating factors, thereby distinguishing itself as...
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abela, J., & Hankin, B. (2008). Cognitive vulnerability to depression in children and adolescents: A developmental psychopathology perspective. In J. Abela & B. Hankin (Eds.), Handbook of depression in children and adolescents (pp. 35–78). New York: The Guilford Press.
American Academy of Child and Adolescent Psychiatry. (2009). Practice parameters on the use of psychotropic medication in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 48(9), 961–973.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th text revision [DSM IV-TR] ed). Washington, DC: American Psychiatric Publishing.
Amminger, G. P., Schafer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., et al. (2010). Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Archives of General Psychiatry, 67(2), 146–154.
Andersen, S. L., & Teicher, M. H. (2008). Stress, sensitive periods and maturational events in adolescent depression. Trends in Neuroscience, 31(4), 183–191.
Asarnow, J., Jaycox, L., Duan, N., LaBorde, A., Rea, M., Murray, P., et al. (2005). Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: A randomized controlled trial. Journal of the American Medical Association, 293, 311–319.
Barkley, R. (1997). Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychological Bulletin, 121(1), 65–94.
Bhagwagar, Z., Wylezinska, M., Taylor, M., Jezzard, P., Matthews, P. M., & Cowen, P. J. (2004). Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. American Journal of Psychiatry, 161(2), 368–370.
Biederman, J., Faraone, S., Milberger, S., Guite, J., Mick, E., Chen, L., et al. (1996). A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Archives of General Psychiatry, 53(5), 437–446.
Biederman, J., Wilens, T., Mick, E., Spencer, T., & Faraone, S. V. (1999). Pharmacotherapy of attention-deficit hyperactivity disorder reduces risk for substance use disorder. Pediatrics, 104(2), e20–e20.
Birmaher, B., Axelson, D., Monk, K., Kalas, C., Clark, D., Ehmann, M., et al. (2003). Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 42(4), 415–422.
Birmaher, B., Ryan, N., Williamson, D., Brent, D., Kaufman, J., Dahl, R., et al. (1996). Childhood and adolescent depression: A review of the past ten years, Part I. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1427–1439.
Bloom, B. (1979). Prevention of mental disorders: Recent advances in theory and practice. Community Mental Health Journal, 15(3), 179–191.
Brent, D., Poling, K., McKain, B., & Baugher, M. (1993). A psychoeducational program for families of affectively ill children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 32(4), 770–774.
Bridge, J., Iyengar, S., Salary, C., Barbe, R., Birmaher, B., Pincus, H., et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. Journal of the American Medical Association, 297, 1683–1696.
Brown, R., Amler, R., Freeman, W., Perrin, J., Stein, M., Feldman, H., et al. (2005). Treatment of attention-deficit/hyperactivity disorder: Overview of the evidence. Pediatrics, 115(6), 749–757.
Buitelaar, J., & Kooij, J. (2000). Attention deficit hyperactivity disorder (ADHD): Etiology, diagnosis and treatment. Nederlands Tijdschrift voor Geneeskunde, 144(36), 1716–1723.
Cannon, T. D., Cornblatt, B., & McGorry, P. (2007). The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophrenia Bulletin, 33(3), 661–664.
Caplan, G. (1964). Principles of preventive psychiatry. New York: Basic Books.
Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., et al. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTTgene. Science, 301, 386–389.
Cohen, J., Mannarino, A., Perel, J., & Staron, V. (2007). A pilot randomized trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. Journal of the American Academy of Child and Adolescent Psychiatry, 46(7), 811–819.
Comer, J., Olfson, M., & Mojtaba, R. (2010). National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. Journal of the American Academy of Child and Adolescent Psychiatry, 49(10), 1001–1010.
Costello, E., Farmer, E., Angold, A., Burns, B., & Erkanli, A. (1997). Psychiatric disorders among American Indian and white youth in Appalachia: The great Smoky Mountains study. American Journal of Public Health, 87(5), 827–832.
Curtis, L., & Patel, K. (2008). Nutritional and environmental approaches to preventing and treating autism and Attention Deficit Hyperactivity Disorder (ADHD): A review. The Journal of Alternative and Complementary Medicine, 14(1), 79–85.
De Bellis, M., Casey, B., Re, D., Birmaher, B., Williamson, D., Thomas, K., et al. (2000). A pilot study of amygdala volumes in pediatric generalized anxiety disorder. Biological Psychiatry, 48(1), 51–57.
De Koning, M. B. (2009). Early intervention in patients at ultra high risk of psychosis: Benefits and risks. Acta psychiatrica scandinavica, 119(6), 426–442.
Diamond, G., & Josephson, A. (2005). Family-based treatment research: A 10-year update. Journal of the American Academy of Child and Adolescent Psychiatry, 44(9), 872–887.
Eaton, W. W., Badawi, M., & Melton, B. (1995). Prodromes and precursors: Epidemiologic data for primary prevention of disorders with slow onset. American Journal of Psychiatry, 152(7), 967–972.
Epstein, J., Casey, B., Tonev, S., Davidson, M., Reiss, A., Garrett, A., et al. (2007). ADHD- and medication-related brain activation effects in concordantly affected parent-child dyads with ADHD. Journal of Child Psychology & Psychiatry, and Allied Disciplines, 48(9), 899–913.
Famularo, R., Kinscherff, R., & Fenton, T. (1988). Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. The American Journal of Diseases of Children, 142(11), 1244–1247.
Feldner, M., & Zvolensky, M. (2004). Prevention and anxiety psychopathology: A critical review of the empirical literature. Clinical Psychology: Science and Practice, 11(4), 405–424.
Flannery-Schroeder, E. (2006). Reducing anxiety to prevent depression. American Journal of Preventive Medicine, 6(1), 136–142.
Garber, J., Clarke, G., Weersing, V., Beardslee, W., Brent, D., Gladstone, T., et al. (2009). Prevention of depression in at-risk adolescents: A randomized controlled trial. Journal of the American Medical Association, 301(21), 2215–2224.
Geller, D., Hoog, S., Heiligenstein, J., Ricardi, R., Tamura, R., Kluszynski, S., et al. (2001). Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40(7), 773–779.
Ginsburg, G., Kendall, P., Sakolsky, D., Compton, S., Piacentini, J., Albano, A., et al. (2011). Remission after acute treatment in children and adolescents with anxiety disorders: Findings from the CAMS. Journal of Consulting and Clinical Psychology, 79(6), 806–813.
Goodyear, P., & Hynd, G. (1992). Attention deficit disorder with (ADD/H) and without (ADD/WO) hyperactivity: Behavioral and neuropsychological differentiation. Journal of Clinical Child Psychology, 21(3), 273–305.
Goodyer, I., Dubicka, B., Wilkinson, P., Kelvin, R., Roberts, C., Byford, S., et al. (2007). Selective serotonin reuptake inhibitors (SSRI’s) and routine specialist care with and without cognitive behavior therapy in adolescents with major depression: Randomized controlled trial. British Medical Journal, 335(7611), 142–146.
Grady, D., Chi, H., Ding, Y., Smith, M., Wang, E., Schuck, S., et al. (2003). High prevalence of rare dopamine receptor D4 alleles in children diagnosed with attention-deficit hyperactivity disorder. Molecular Psychiatry, 8(5), 536–545.
Harmon, R., & Riggs, P. (1996). Clonidine for posttraumatic stress disorder in preschool children. Journal of the American Academy of Child and Adolescent Psychiatry, 35(9), 1247–1249.
Herman-Stahl, M., Krebs, C., Kroutil, L., & Heller, D. (2006). Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents. Journal of Adolescent Health, 39, 374–380.
Hetrick, S., Merry, S., McKenzie, J., Sindahl, P., & Proctor, M. (2009). Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents (review). The Cochrane Collaboration, 1, 1–62.
Hughes, C., Emslie, G., Crismon, M., Posner, K., Birmaher, B., Ryan, N., et al. (2007). Texas children’s medication algorithm project: Update from Texas conference panel on medication treatment of childhood major depressive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(6), 667–686.
Jain, R., Segal, S., Kollins, S., & Khayrallah, M. (2011). Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 50(2), 171–179.
Jensen, P. (2000). Current concepts and controversies in the diagnosis and treatment of attention deficit hyperactivity disorder. Current Psychiatry Reports, 2(2), 102–109.
Jensen, P., Hinshaw, S., Swanson, J., Greenhill, L., Conners, C., Arnold, L., et al. (2001). Findings from the NIMH multimodal treatment study of ADHD (MTA): Implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics, 22(1), 60–73.
Kaloyanides, K., McCabe, S., Cranford, J., & Teter, C. (2007). Prevalence of illicit use and abuse of prescription stimulants, alcohol, and other drugs among college students: Relationship with age at initiation of prescription stimulants. Pharmacotherapy, 27(5), 666–674.
Katusic, S., Barbaresi, W., Colligan, R., Weaver, A., Leibson, C., & Jacobsen, S. (2005). Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: A population-based, birth cohort study. Journal of Child and Adolescent Psychopharmacology, 15(5), 764–776.
Kessler, R., Avenevoli, S., McLaughlin, K., Green, J., Lakoma, M., Petukhova, M., et al. (2012). Lifetime co-morbidity of DSM-IV disorders in the US national comorbidity survey replication adolescent supplement (NCS-A). Psychological Medicine, 42(09), 1–14.
Kessler, R., & Price, R. (1993). Primary prevention of secondary disorders: A proposal and agenda. American Journal of Community Psychology, 21(5), 607–633.
Kollins, S., Jain, R., Brams, M., Segal, S., Findling, R., Wigal, S., et al. (2011). Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics, 127(6), e1406–e1413.
Lou, H. (1996). Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): Significance of prematurity and perinatal hypoxic-haemodynamic encephalopathy. Acta Paediatrica, 85(11), 1266–1271.
March, J., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E., et al. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. Journal of the American Medical Association, 280(20), 1752–1756.
Marshall, M., & Rathbone, J. (2011). Early intervention for psychosis. Schizophrenia Bulletin, 37(6), 1111–1114.
May, D., & Kratochvil, C. (2010). Attention-deficit hyperactivity disorder: Recent advances in paediatric pharmacotherapy. Drugs, 70(1), 15–40.
McCabe, S., West, B., Teter, C., Ross-Durow, P., Young, A., & Boyd, C. (2011). Characteristics associated with the diversion of controlled medications among adolescents. Drug and Alcohol Dependence, 118, 452–458.
McClellan, J., & Werry, J. (1994). American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 33(5), 616–635.
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., et al. (2009). Intervention in individuals at ultra-high risk for psychosis: A review and future directions. Journal of Clinical Psychiatry, 70(9), 1206–1212.
Merikangas, K., He, J., Brody, D., Fisher, P., Bourdon, K., Koretz, D., et al. (2010a). Prevalence and treatment of mental disorders among U.S. children in the 2001–2004 NHANES. Pediatrics, 125(1), 75–81.
Merikangas, K., He, J., Burstein, M., Swanson, S., Avenevoli, S., Cui, L., et al. (2010b). Lifetime prevalence of mental disorders in U.S. adolescents: Results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). Journal of the American Academy of Child and Adolescent Psychiatry, 49(10), 980–989.
Merikangas, K., He, J., Burstein, M., Swendsen, J., Avenevoli, S., Case, B., et al. (2011). Service utilization for lifetime mental disorders in U.S. adolescents: Results of the National Comorbidity Survey-Adolescent Supplement (NCS-A). American Academy of Child and Adolescent Psychiatry, 50(1), 32–45.
Milham, M., Nugent, A., Drevets, W., Dickstein, D., Leibenluft, E., Ernst, M., et al. (2005). Selective reduction in amygdala volume in pediatric anxiety disorders: A voxel-based morphometry investigation. Biological Psychiatry, 57(9), 961–966.
Millichap, J. (2008). Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics, 121(2), 358–365.
Molina, B., Hinshaw, S., Swanson, J., Arnold, L., Vitiello, B., Jensen, P., et al. (2009). The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry, 48(5), 484–500.
Mrezek, P., & Haggerty, R. (1994). Reducing risks for mental disorders: Frontiers for preventive intervention research. Washington, DC: National Academy Press.
MTA Cooperative Group. (2004). National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics, 113(4), 754–761.
Mufson, L., Dortka, K., Wickramaratne, P., Nomura, Y., Olfson, M., & Weissman, M. (2004). A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Archives of General Psychiatry, 61(6), 577–584.
Nair, V., & Mahadevan, S. (2009). Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD. Journal of Tropical Pediatrics, 55(2), 116–121.
Olfson, M., Shaffer, D., Marcus, S., & Greenburg, T. (2003). Relationship between antidepressant medication treatment and suicide in adolescents. Archives of General Psychiatry, 60(10), 978–982.
Paunesku, D., Ellis, J., Fogel, J., Kuwabara, S., Gollan, J., Gladstone, T., et al. (2008). Clusters of behaviors and beliefs predicting adolescent depression: Implications for prevention. Journal of Cognitive and Behavioral Psychotherapies, 8(2), 147–168.
Picchioni, M. M., & Murray, R. M. (2007). Schizophrenia. British Medical Journal, 335(7610), 91–95.
Pine, D. (2007). Research review: A neuroscience framework for pediatric anxiety disorders. Journal of Child Psychology & Psychiatry, 48(7), 631–648.
Quinn, P., & Nadeau, G. (1999). Understanding girls with AD/HD – Part 1 improving the identification of girls with AD/HD. In G. Nadeau, E. Littman, & P. Quinn (Eds.), Understanding girls with ADHD. Silver Spring, MD: Advantage Books.
Rains, A., Scahill, L., & Hamrin, V. (2006). Nonstimulant medications for the treatment of ADHD. Journal of Child and Adolescent Psychiatric Nursing, 19(1), 44–47.
Renaud, J., Brent, D., Baugher, M., Birmaher, B., Kolko, D., & Bridge, J. (1998). Rapid response to psychosocial treatment for adolescent depression: A two-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry, 37(11), 1184–1190.
Riddle, M., Reeve, E., Yaryura-Tobias, J., Yang, H., Claghorn, J., & Gaffney, G. (2001). Fluvoxamine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40(2), 222–229.
Risch, N., Herrell, R., Lehner, T., Liang, K., Eaves, L., Hoh, J., et al. (2009). Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression. Journal of the American Medical Association, 301(23), 2462–2471.
Rynn, M., Siqueland, L., & Rickels, K. (2001). Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. American Journal of Psychiatry, 158(12), 2008–2014.
Sanford, M., Boyle, M., McCleary, L., Miller, J., Steele, M., Duku, E., et al. (2006). A pilot study of adjunctive family psychoeducation in adolescent major depression: Feasibility and treatment effect. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 386–495.
Saxe, G., Stoddard, F., Courtney, D., Cunningham, K., Chawla, N., Sheridan, R., et al. (2001). Relationship between acute morphine and the course of PTSD in children with burns. Journal of the American Academy of Child and Adolescent Psychiatry, 40(8), 915–921.
Seedat, S., Stein, D., Ziervogel, C., Middleton, T., Kaminer, D., Emsley, R., et al. (2002). Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. Journal of Child and Adolescent Psychopharmacology, 12(1), 37–46.
Swanson, J., Kinsbourne, M., Nigg, J., Lanphear, B., Stefanatos, G., Volkow, N., et al. (2007). Etiologic subtypes of attention-deficit/hyperactivity disorder: Brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychology Review, 17(1), 39–59.
Swanson, J., Kraemer, H., Hinshaw, S., Arnold, L., Conners, C., Abikoff, H., et al. (2001). Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 40(2), 168–179.
Swanson, J., Sunohara, G., Kennedy, J., Regino, R., Fineberg, E., Wigal, T., et al. (1998). Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): A family-based approach. Molecular Psychiatry, 3(1), 38–41.
Treatment for Adolescents with Depression Study (TADS) Team, March, J., Silva, S., Curry, J., Wells, K., Fairbank, J., et al., (2009, October). The treatment for adolescents with depression study (TADS): Outcomes over 1 year of naturalistic follow-up. American Journal of Psychiatry, 166, 1141–1149.
U.S. Department of Health and Human Services. (1999). Mental health: A report of the surgeon general – Executive summary. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health.
Uher, R., & McGuffin, P. (2010). The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression. Molecular Psychiatry, 15, 18–22.
van der Meer, F. J., Velthorst, E., Meijer, C. J., Machielsen, M. W., & de Haan, L. (2012). Cannabis use in patients at clinical high risk of psychosis: Impact on prodromal symptoms and transition to psychosis. Current Pharmaceutical Design, 18(32), 5036–5044.
van Os, J., & Kapur, S. (2009). Schizophrenia. The Lancet, 374(9690), 635–645.
van Voorhees, B., Paunesku, D., Kuwabara, S., Basu, A., Gollan, J., Hankin, B., et al. (2008). Protective and vulnerability factors predicting new-onset depressive episode in a representative of U.S. adolescents. The Journal of Adolescent Health, 42(6), 605–616.
Wang, P., Lane, M., Olfson, M., Pincus, H., Wells, K., & Kessler, R. (2005). Twelve month use of mental health services in the United States: Results from the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 629–640.
Weersing, V., Iyengar, S., Kolko, D., Birmaher, B., & Brent, D. (2006). Effectiveness of a cognitive-behavioral therapy for adolescent depression: A benchmarking investigation. Behavioral Therapy, 37(1), 36–48.
Weissman, M., Pilowsky, P., Wickramaratne, P., Talati, A., Wisniewski, S., Fava, M., et al. (2006). Remissions in maternal depression and child psychopathology: A STAR*D-child report. Journal of the American Medical Association, 22, 1389–1399.
Weisz, J., McCarty, C., & Valeri, S. (2006). Effects of psychotherapy for depression in children and adolescents: A meta-analysis. Psychological Bulletin, 132, 132–149.
Wilens, T. E., Adamson, J., Monuteaux, M. C., Faraone, S. V., Schillinger, M., Westerberg, D., et al. (2008). Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Archives of Pediatrics and Adolescent Medicine, 162(10), 916–921.
Wilens, T., Bukstein, O., Brams, M., Cutler, A., Childress, A., Rugino, T., et al. (2012). A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(1), 74–85.
Zohar, J., Sonnino, R., Juven-Wetzler, A., & Hagit, C. (2009). Can posttraumatic stress disorder be prevented? CNS Spectrum, 14(1), 44–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this entry
Cite this entry
Rayapati, A., Venugopalakrishnan, J., Gandham, L., Kanga, F.H., Martin, C.A. (2014). Medications and Mental Health. In: Gullotta, T.P., Bloom, M. (eds) Encyclopedia of Primary Prevention and Health Promotion. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-5999-6_196
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5999-6_196
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-5998-9
Online ISBN: 978-1-4614-5999-6
eBook Packages: MedicineReference Module Medicine